Kalos Management, Inc. - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 29 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Kalos Management, Inc. ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$24,000
-53.8%
72,858
+0.0%
0.01%
-50.0%
Q2 2020$52,000
+116.7%
72,850
+0.0%
0.02%
+100.0%
Q1 2020$24,000
-50.0%
72,849
+8.9%
0.01%
-35.3%
Q4 2019$48,000
+4.3%
66,9000.0%0.02%
-5.6%
Q3 2019$46,000
-58.6%
66,9000.0%0.02%
-64.0%
Q2 2019$111,000
-30.2%
66,900
+5.0%
0.05%
-51.5%
Q1 2019$159,000
-11.2%
63,724
-14.4%
0.10%
+18.4%
Q4 2018$179,000
-41.9%
74,420
+6.5%
0.09%
-47.3%
Q3 2018$308,000
+124.8%
69,900
+83.9%
0.16%
+166.1%
Q2 2018$137,000
-50.0%
38,000
-50.0%
0.06%
-23.5%
Q1 2018$274,00076,0000.08%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 535,590$2,705,0001.58%
Millrace Asset Group, Inc. 200,000$1,010,0000.79%
Private Wealth Partners, LLC 1,000,000$5,050,0000.77%
PERKINS CAPITAL MANAGEMENT INC 249,700$1,261,0000.76%
Timpani Capital Management LLC 206,119$1,041,0000.30%
Diametric Capital, LP 64,329$325,0000.28%
Granahan Investment Management 941,170$4,753,0000.26%
Kalos Management, Inc. 69,900$308,0000.16%
SYMMETRY PEAK MANAGEMENT LLC 85,000$429,0000.15%
B. Riley Wealth Advisors, Inc. 250,000$1,263,0000.15%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders